Ecor1 Capital Fund Qualified, Sells 3,209,316 Shares of aTyr Pharma, Inc. (LIFE) Stock

aTyr Pharma, Inc. (NASDAQ:LIFE) major shareholder Ecor1 Capital Fund Qualified, sold 3,209,316 shares of the business’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $0.93, for a total transaction of $2,984,663.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of aTyr Pharma opened at $0.97 on Friday, Marketbeat.com reports. The stock has a market cap of $40.23 million, a PE ratio of -0.52 and a beta of 3.49. The company has a quick ratio of 8.37, a current ratio of 6.72 and a debt-to-equity ratio of 0.24. aTyr Pharma, Inc. has a 12 month low of $1.20 and a 12 month high of $1.30.

aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Monday, March 19th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. equities analysts anticipate that aTyr Pharma, Inc. will post -1.2 earnings per share for the current year.

Several analysts have weighed in on LIFE shares. ValuEngine raised shares of aTyr Pharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Friday, March 9th. Piper Jaffray reissued an “overweight” rating and issued a $3.00 price target on shares of aTyr Pharma in a research note on Monday. JPMorgan Chase downgraded shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Finally, Citigroup downgraded shares of aTyr Pharma from a “neutral” rating to a “sell” rating in a research note on Monday. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. aTyr Pharma presently has an average rating of “Hold” and a consensus price target of $3.33.

Several large investors have recently modified their holdings of the company. Sofinnova Ventures Inc bought a new position in shares of aTyr Pharma during the first quarter valued at about $4,945,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 33.5% during the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 28,699 shares during the last quarter. Deutsche Bank AG bought a new position in shares of aTyr Pharma during the fourth quarter valued at about $199,000. Renaissance Technologies LLC raised its stake in shares of aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after acquiring an additional 164,500 shares during the last quarter. Finally, Artal Group S.A. raised its stake in shares of aTyr Pharma by 100.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $1,750,000 after acquiring an additional 250,000 shares during the last quarter. 58.91% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit